Bosentan is a mixed Endothelin Receptor Antagonist which is used as a vasodilator. Bosentan is an inhibitor of ETAR and ETBR. It is used for the treatment of pulmonary artery hypertension (PAH). Bosentan blocks the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
Raju, K. Rajasekhara; Reddy, B. Shankar; Somannavar, Y. S.; Sinha, B. K.; Babu, P. N. Kishore; Raju, K. Mohana. Improved Large-Scale Synthesis of Bosentan Monohydrate. Organic Preparations and Procedures International. Chemical Research and Development. Aurobindo Pharma Ltd. Telangana, India. Volume 48. Issue 6. Pages 481-491. 2016
Gudekar, Sanket; Lokhande, Rama; Sutar, Rajiv; Pednekar, Sanjay; Surve, Sandip; Kolhal, Surekha. Synthesis and characterisation of process related impurity in Bosentan Monohydrate. Journal of Chemical and Pharmaceutical Research. School of Basic Sciences, Department of Chemistry. Jaipur National University. Jaipur, India. Volume 5. Issue 11. Pages 600-604, 5 pp.2013
Rebelli, Pradeep; Yerrabelly, Jayaprakash Rao; Yalamanchili, Bharathi kumari; Kommera, Rajashekar; Ghojala, Venkat Reddy; Bairy, Kondal Reddy. New approaches to endothelin receptor antagonist – bosentan. Letters in Organic Chemistry. Department of Research and Development. MSN R and D centre. Medak, Andhra Pradesh, India 502307. Volume 10. Issue 5. Pages 364-368. 2013
Lee, Chung Ryul; Lee, Sang Yeul; Nam, Tae-gyu. Succinct Synthesis of Bosentan Utilizing Glycol Mono-THP Ether. Synthetic Communications. Department of Pharmacy and Institute of Pharmaceutical Science and Technology. Hanyang University. Gyeonggi-do, S. Korea. Volume 44. Issue 17. Pages 2488-2493. 2014
Harrington, Peter J.; Khatri, Hiralal N.; DeHoff, Brad S.; Guinn, Martin R.; Boehler, Mark A.; Glaser, Karl A. Research and Development of a Second-Generation Process for Bosentan, an Endothelin Receptor Antagonist. Organic Process Research & Development. Boulder Technology Center. Roche Colorado Corporation. Boulder, USA 80301. Volume 6. Issue 2. Pages 120-124. 2002
Bolli, Martin H.; Boss, Christoph; Binkert, Christoph; Buchmann, Stephan; Bur, Daniel; Hess, Patrick; Iglarz, Marc; Meyer, Solange; Rein, Josiane; Rey, Markus; Treiber, Alexander; Clozel, Martine; Fischli, Walter; Weller, Thomas. The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist. Journal of Medicinal Chemistry. Drug Discovery Chemistry. Actelion Pharmaceuticals Ltd.. Allschwil, Switz. CH-4123.Volume 55 Issue 17. Pages 7849-7861. 2012
Yang, Ning; Dong, Junjun; Liu, Keliang. Synthesis of bosentan as an endothelin receptor antagonist. Zhongguo Yaowu Huaxue Zazhi. Institute of Pharmacology and Toxicology. Academy of Military Medical Sciences. Beijing, Peop. Rep. China 100850. Volume 15. Issue 4. Pages 230-233. 2005
Yang, Yi-hong; Yin, Di; Zhang, Heng. On synthesis of bosentan. Wuhan Gongcheng Daxue Xuebao. Key Laboratory for Green Chemical Process of Ministry of Education. Wuhan Institute of Technology. Wuhan, Hubei Province, Peop. Rep. China 430074. Volume 34. Issue 12. Pages 1-3, 7 2012
Shimpi, Nitin; Jaware, Jalindar; Bijukumar, Gopinathan Pillai; Prabhavat, Manoj Devilalji; Nadkarni, Sunil Sadanand. Process for the preparation of bosentan. Assignee Torrent Pharmaceuticals Ltd., India. IN 2009MU01366. 2010
Gant, Thomas G.; Sarshar, Sepehr. Substituted pyrimidines as endothelin modulators and their preparation and use in the treatment of diseases. Assignee Auspex Pharmaceuticals, Inc., USA. US 20080242687. 2008
